MDMA Co-administration Investigated to Enhance Positive, Reduce Negative LSD Experiences in Healthy Subjects

Lysergic acid diethylamide (LSD), primarily stimulating the 5-HT2A receptor, often induces positive subjective effects but can also cause negative experiences like anxiety, paranoid thinking, or loss of trust. These negative effects are influenced by dose, individual personality (set), and environment (setting), and are linked to less favorable long-term outcomes in patients treated for depression. 3,4-methylenedioxymethamphetamine (MDMA), a 5-HT and oxytocin releaser, reliably fosters positive mood, euphoria, comfort, empathy, and trust. Combining MDMA with LSD is hypothesized to amplify positive subjective effects while mitigating the negative emotional and anxious responses often associated with LSD.

This study describes a planned investigation into the acute subjective and autonomic effects of LSD alone and in combination with MDMA in healthy human subjects. The primary objective is to determine if MDMA co-administration can increase positive subjective drug effects, including positive mood, empathy, and trust, while simultaneously reducing negative emotions and anxiety typically associated with LSD. The study aims to evaluate if this combination leads to a more positive overall experience compared to LSD administered alone, assessing various subjective and autonomic endpoints.

This abstract outlines the rationale and design for a planned study; therefore, no experimental results or specific findings are reported. The study aims to investigate the subjective and autonomic effects of LSD alone versus in combination with MDMA, but the outcomes of these assessments are not yet available. No data, statistics, or p-values are presented from an executed trial.